Enalare Therapeutics Announces First Subject Dosed With Lead Product ENA-001 in a Propofol-Induced Respiratory Depression Study
Nov 4, 2021
Enalare Therapeutics Inc., a biopharmaceutical company dedicated to developing novel therapies for patients suffering from life-threatening critical care conditions, announced today that it has dosed the first subject with its lead product ENA-001 in a propofol-induced respiratory depression study. This study aims to demonstrate the ability of ENA-001 to reverse respiratory depression induced through administration of propofol, a central nervous system depressant commonly utilized globally as a surgical anesthetic. To date, there is no approved product indicated for the reversal of respiratory depression induced by propofol.
"We are excited to have initiated this important study for our lead product ENA-001," stated Joseph Pergolizzi, MD, Chief Research and Development Officer of Enalare. "We believe ENA-001 has the potential to significantly improve the standard of care for many patients experiencing life-threatening respiratory depression, including due to drug overdose, post-operative conditions, and apnea of prematurity. This study will further highlight the profile of ENA-001 as a potentially effective and safe agnostic respiratory stimulant, and provide valuable information for the product's clinical program moving forward."
About ENA-001
Enalare's lead product ENA-001 is a one-of-a-kind new chemical entity designed as an agnostic respiratory stimulant. The product has a unique mechanism of action that affects ventilation via the peripheral chemoreceptor pathways in the carotid body. The product utilizes the body's own ventilation control system to beneficially influence breathing and has been shown to be effective and well-tolerated in four previous human studies.
About the Clinical Study
The study is being conducted under the direction of Dr. Albert Dahan, a renowned leader in the field of breathing control mechanisms, at the Leiden University Medical Center, the Netherlands. Dosing regimens are being explored that are expected to restore ventilatory sufficiency under normal sedation, show increased ventilatory responsiveness to hypoxemic events and avert ventilatory degradation during periods of clamped hypercapnia, all while preserving the analgesic effects of propofol.
About Enalare Therapeutics Inc.
Enalare Therapeutics Inc. is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for patients suffering from life-threatening acute respiratory and critical care conditions, including drug overdose, post-surgery respiratory depression, and apnea of prematurity. The Company is planning to initiate additional clinical studies for ENA-001 across multiple indications in the coming year.
Contact:
Morgan Wagner
Enalare Investor Relations
[email protected]
Press Release Service by Newswire.com
Original Source: Enalare Therapeutics Announces First Subject Dosed With Lead Product ENA-001 in a Propofol-Induced Respiratory Depression Study
More News
‘Biggest hack in history’: Crypto giant freezes assets after $8.9b heist
Binance says a security breach had resulted in an estimated $8.9 billion impact. Analysts said it could amount to the biggest crypto heist ever.
Big Hits: New Murchison Gold, Elk Range Mining and WhiteRock Lithium
Big Hits looks at notable drill intercepts reported to the ASX this week, led by New Murchison Gold in WA, with runners-up Elk Range Mining in Idaho and WhiteRock Lithium in Quebec.
ASX Runners of the Week: NGX Limited, RBR Group and Eden Innovations
This week’s Bulls N’ Bears ASX Runner of the Week is… NGX Limited, soaring 92.9% on deals for seven Namibian gold licences covering more than 1300 square kilometres.
Billions wiped off Coles as it loses ground to Woolworths
Coles shares have plunged after a profit warning, amid signs of stiff competition with arch-rival Woolworths.
Raiz funds swell to $2.4b riding young investor wave
Raiz Invest’s funds under management grew 20.2 per cent to $2.4 billion in the September quarter, as younger investors drove customer growth and $69 million flowed onto its platform.
Annie Cannon-Brookes’ paddock-to-plate precinct under investigation
The billionaire’s regenerative farm and hospitality venture in the Southern Highlands is facing questions from council over its development approval.
ASX finishes the week higher as bank shares improve
The Australian sharemarket ended the week higher, after three of the big four banks gained on Friday.
Our OH&S officer is on a power trip. How do we make them stop?
I can see how frustrating, and sometimes offensive, this person’s behaviour is. But there might be a hidden reason for it.
Coles sacked a worker for grabbing a shoplifter. As a lawyer, here’s why it was the right call
When I worked at a suburban Woolworths I saw outrageous theft. The store managers would tackle thieves to the ground in the car park.
‘Just try me’: The text messages that sparked News24’s on-air clash
New text messages between One Nation’s James Ashby and News24’s Andrew Clennell reveal some of the power dynamics playing out in Canberra.
I jumped into a driverless car in the US. Here’s how they could hit Australia
Trips in a Waymo tend to cost more than Uber rides and are likely to put drivers out of jobs. So, what are the benefits, and do we want these cars on our roads?
Sydney’s classic Roseville Cinema will stay open and independent after $8m sale
The brothers behind Queensland-based picture theatre business Five Star Cinemas purchased the historic venue.
YOUR NEWS, OUR NETWORK.
Do you have Great News you want to tell the world?
Be it updates about your business or your community, you can make sure that it’s heard by submitting your story to our network reaching hundreds of news sites across 6 verticals.